Daniel Dever - GRPH Old CoFounder Research
| GRPHDelisted Stock | USD 2.67 0.05 1.84% |
Insider
Daniel Dever is CoFounder Research of GRPH Old
| Phone | 650 484 0886 |
| Web | https://graphitebio.com |
GRPH Old Management Efficiency
The company has return on total asset (ROA) of (0.1799) % which means that it has lost $0.1799 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5195) %, meaning that it created substantial loss on money invested by shareholders. GRPH Old's management efficiency ratios could be used to measure how well GRPH Old manages its routine affairs as well as how well it operates its assets and liabilities.GRPH Old currently holds 362 K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. GRPH Old has a current ratio of 26.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about GRPH Old's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Timothy Moore | Instil Bio | 63 | |
| Julia Wilson | Achilles Therapeutics PLC | N/A | |
| Sandeep MD | Instil Bio | 56 | |
| Robert Bazemore | Nuvation Bio | 53 | |
| Bronson Crouch | Instil Bio | 52 | |
| Kerry Wentworth | Nuvation Bio | 52 | |
| Mark Dudley | Instil Bio | N/A | |
| MBA BS | CytomX Therapeutics | 46 | |
| Karl MD | Achilles Therapeutics PLC | 57 | |
| CPA CPA | NextCure | 61 | |
| MD FACP | NextCure | 71 | |
| Christopher JD | Sensei Biotherapeutics | N/A | |
| Thomas Templeman | Nuvation Bio | 60 | |
| Michael MSBA | NextCure | 64 | |
| Oleg Nodelman | Nuvation Bio | 44 | |
| Tharaknath Rao | Assembly Biosciences | N/A | |
| FMEDSCI MD | Achilles Therapeutics PLC | 49 | |
| MBA MBA | Sensei Biotherapeutics | 52 | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| Elisabeth Colunio | Sensei Biotherapeutics | N/A | |
Management Performance
| Return On Equity | -0.52 | |||
| Return On Asset | -0.18 |
GRPH Old Leadership Team
Elected by the shareholders, the GRPH Old's board of directors comprises two types of representatives: GRPH Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GRPH. The board's role is to monitor GRPH Old's management team and ensure that shareholders' interests are well served. GRPH Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GRPH Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephanie Yao, Vice Relations | ||
| Maria MD, Academic Board | ||
| Christine PMP, Chief Operations | ||
| Jerry Cacia, Chief Officer | ||
| Philip Gutry, Chief Officer | ||
| Jane Grogan, Chief Officer | ||
| MD FACC, CEO Pres | ||
| Daniel Dever, CoFounder Research | ||
| Alethia Young, Chief Officer | ||
| Kimberlee CPA, CEO and Presidentident | ||
| Matthew MD, Academic Director |
GRPH Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GRPH Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | |||
| Return On Asset | -0.18 | |||
| Current Valuation | 1.88 M | |||
| Shares Outstanding | 58.24 M | |||
| Shares Owned By Insiders | 9.17 % | |||
| Shares Owned By Institutions | 84.40 % | |||
| Number Of Shares Shorted | 704.04 K | |||
| Price To Earning | 0.70 X | |||
| Price To Book | 1.01 X | |||
| EBITDA | (70.7 M) |
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in GRPH Stock
If you are still planning to invest in GRPH Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GRPH Old's history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |